Cirrhosis, Liver Clinical Trial
Official title:
To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial.
Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 2023 |
Est. primary completion date | October 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology who consent for enrolment. - Hypotension (Mean arterial pressure <65mmHg or Systolic blood pressure <90mmHg) - Aged between18-65 yrs Exclusion Criteria: - Already received colloid or more than 2 litres of fluid without baseline echocardiographic assessment. - Already on vasopressors/inotropes - Severe pre-existing cardiopulmonary disease - Acute Respiratory Distress Syndrome (ARDS) - Active bleeding like variceal bleed - Cerebrovascular events - Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy - Admission to ICU following liver transplantation, burns, cardiac surgery - Brain death or likely brain death within 24 hours - Previous adverse reaction to human albumin solution - Pregnant or lactating women - Informed consent refused by patient or attendants |
Country | Name | City | State |
---|---|---|---|
India | Postgraduate Institute of Medical Education and Research | Chandigarh |
Lead Sponsor | Collaborator |
---|---|
Postgraduate Institute of Medical Education and Research |
India,
ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1. — View Citation
Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001 Jan-Feb;33(1):41-8. — View Citation
Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 Jul;134(1):172-8. doi: 10.1378/chest.07-2331. Review. — View Citation
Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992 Jun;20(6):746-50. — View Citation
Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, Coats TJ, Singer M, Young JD, Rowan KM; ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015 Apr 2;372(14):1301-11. doi: 10.1056/NEJMoa1500896. Epub 2015 Mar 17. — View Citation
Navasa M, Fernández J, Rodés J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol. 1999 Oct;31(7):616-25. Review. — View Citation
Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M; International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005 May;54(5):718-25. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics. | To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension | At enrolment | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics. | To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension | At 6 hours | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics. | To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension | At 24 hours | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics. | To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension | At 48 hours. | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters. | To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension | At enrolment | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters. | To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension | At 24 hours | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters. | To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension | At 48 hours. | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI) | To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension | At enrolment | |
Primary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI) | To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension | At 48 hours. | |
Secondary | Urinary marker of AKI (NGal) | At enrolment | ||
Secondary | Change in urinary markers of AKI (NGal) | At 24 hours. | ||
Secondary | Change in urinary markers of AKI(NGal) | At 48 hours. | ||
Secondary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement | To compare the vasopressor requirement in patients with cirrhosis and sepsis induced hypotension | At enrolment | |
Secondary | To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement | To compare the vasopressor requirement in patients with cirrhosis and sepsis induced hypotension | At 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
Recruiting |
NCT05604274 -
Longitudinal Monitoring of Stool Characteristics
|
||
Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|